Novo Nordisk looks to expand Latin American obesity business

COPENHAGEN (Reuters) - Danish drugmaker Novo Nordisk is looking to expand its obesity business in Latin America on the back of "phenomenal" performance by its new anti-obesity injection Saxenda, a senior company official said on Monday.